Conventional radiography and correlated factors of enthesopathies of the Achilles tendon and plantar fascia in patients with axial spondyloarthritis

Ebru Yılmaz; Özge Pasin; Loiane Cristina de Souza; Guilherme Torres Vilarino; Alexandro Andrade; Camila Gusmão Vicente de Carvalho; Barbara Bayeh; Fernando Henrique Carlos de Souza; Renata Miossi; Pleiades Tiharu Inaoka; Takashi Matsushita; Naoki Mugii; Samuel Katsuyuki Shinjo

doi:10.4081/reumatismo.2024.1709

Search

Search articles for

Advanced filters

Published AfterYearMonthDay

Published BeforeYearMonthDay

By Author

By Section

Search Results

##search.searchResults.foundPlural##

Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients

S. Canestri, M.C. Totaro, E. Serone, B. Tolusso, D. Frezza, E. Gremese, G. Ferraccioli

368-373

20-12-2012

https://doi.org/10.4081/reumatismo.2012.368

2142

PDF: 780
Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

S.L. Bello, L. Serafino, C. Bonali, N. Terlizzi, C. Fanizza, C. Anecchino, G. Lapaldula

299-306

11-12-2012

https://doi.org/10.4081/reumatismo.2012.299

2253

PDF: 1204
Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study

L. Bazzichi, D. Biasi, E. Tinazzi, M. Muratore, R. Pellerito, R. Russo, M. Corsaro Santi, P. De Sandre, O. Epis, M. Granata, B. Kroegler, C. Meschini, F. Versace, C. Astolfi

224-232

06-11-2014

https://doi.org/10.4081/reumatismo.2014.748

2299

PDF: 1546
Granulomatosis polyangiitis associated with meningeal involvement: response to rituximab therapy after failure of cyclophosphamide

M. Benucci, F. Li Gobbi, P. Panconesi, M. Manfredi, P. Sarzi-Puttini, F. Atzeni

90-94

27-05-2013

https://doi.org/10.4081/reumatismo.2013.90

2446

PDF: 872
Successful treatment of refractory adult onset Still’s disease with rituximab

N. Belfeki, M. Smiti Khanfir, F. Said, A. Hamzaoui, T. Ben Salem, I. Ben Ghorbel, M. Lamloum, M.H. Houman

159-162

16-12-2016

https://doi.org/10.4081/reumatismo.2016.888

2413

PDF: 1176
The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature

S. Barsotti, E. Cioffi, A. Tripoli, A. Tavoni, A. d’Ascanio, M. Mosca, R. Neri

78-84

06-07-2018

https://doi.org/10.4081/reumatismo.2018.1011

2487

PDF: 1305
Are biological drugs safe in pregnancy?

A. Calligaro, A. Hoxha, A. Ruffatti, L. Punzi

304-317

31-03-2015

https://doi.org/10.4081/reumatismo.2014.798

3718

PDF: 2395
Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa

A.A. Akpabio, B.I. Otike-Odibi

115-119

23-07-2020

https://doi.org/10.4081/reumatismo.2020.1274

1048

PDF: 631
Acquired hemophilia A treated with rituximab in a 62-year-old female with rheumatoid arthritis: a case-based review

D. Mohamadzadeh, S. Assar, F. Farsad

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1585

1102

PDF: 334
Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission

B. Cremonezi Lammoglia, L. de Aguiar Trevise, T. Paslar Leal, M. Pereira Lopes Vieira Pinto, G. Hasselmann, N. Salles Rosa Neto

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1588

1252

PDF: 400
Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)

V. Bruzzese, J. Pepe

306-308

https://doi.org/10.4081/reumatismo.2009.306

945

PDF: 762
Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies

Stefano Stano, Fabio Cacciapaglia, Laura Coladonato, Giuseppe Lopalco, Florenzo Iannone, Marco Fornaro

07-04-2025

https://doi.org/10.4081/reumatismo.2025.1817

836

PDF: 221

SUPPLEMENTARY MATERIAL: 87
A short history of anti-rheumatic therapy - VII. Biological agents

G. Pasero, P. Marson, B. Gatto

185-194

09-11-2011

https://doi.org/10.4081/reumatismo.2011.185

1484

PDF: 1219
Polymyositis following varicella and mumps infection in adults: report of two cases

F. Masini, K. Gjeloshi, E. Pinotti, R. Ferrara, C. Romano, G. Cuomo

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1562

1129

PDF: 388
GISEA: an Italian biological agents registry in rheumatology

G. Lapadula, G. Ferraccioli, C. Ferri, L. Punzi, F. Trotta

155-164

09-11-2011

https://doi.org/10.4081/reumatismo.2011.155

2284

PDF: 1540
Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis

M. Fabris, L. Quartuccio, S. Lombardi, M. Benucci, M. Manfredi, M. Saracco, F. Atzeni, P. Morassi, M.A. Cimmino, E. Pontarini, C. Fabro, R. Pellerito, P. Sarzi-Puttini, M. Cutolo, A. Carletto, L.M. Bambara, F. Fischetti, F. Curcio, E. Tonutti, S. De VIta

253-258

https://doi.org/10.4081/reumatismo.2010.253

2058

PDF: 826
Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis

L. Quartuccio, S. Salvin, M. Saracco, S. Lombardi, M. Fabris, E. Mansutti, M. Maset, S. Pellerito, S. De Vita

182-186

https://doi.org/10.4081/reumatismo.2009.182

991

PDF: 694
Safety of rituximab in rheumatoid arthritis

M. Covelli, P. Sarzi-Puttini, F. Atzeni, P. Macchioni

101-106

https://doi.org/10.4081/reumatismo.2010.101

1649

PDF: 991
Anti-N-methyl-d-aspartate receptor encephalitis: mimicker of lupus and multiple sclerosis

N. Sanghavi, B. Ayesha

19-12-2023

https://doi.org/10.4081/reumatismo.2023.1598

1319

PDF: 376
B-cell depletion and primary Sjögren’s syndrome: is there a role for rituximab?

F. Atzeni, P. Sarzi-Puttini

87-88

https://doi.org/10.4081/reumatismo.2010.87

1180

PDF: 634

1 - 20 of 20 items

Search

Search Results

Association between the response to B cell depletion therapy and the allele*2 of the HS1,2A enhancer in seropositive rheumatoid arthritis patients

Incidence of influenza-like illness into a cohort of patients affected by chronic inflammatory rheumatism and treated with biological agents

Safety of rituximab in the routine treatment of rheumatoid arthritis in Italy in patients refractory to anti-TNFa drugs: results from the observational retrospective-prospective RUBINO study

Granulomatosis polyangiitis associated with meningeal involvement: response to rituximab therapy after failure of cyclophosphamide

Successful treatment of refractory adult onset Still’s disease with rituximab

The use of rituximab in idiopathic inflammatory myopathies: description of a monocentric cohort and review of the literature

Are biological drugs safe in pregnancy?

Severe bullous systemic lupus erythematosus successfully treated with low dose rituximab: a case report from sub-Saharan Africa

Acquired hemophilia A treated with rituximab in a 62-year-old female with rheumatoid arthritis: a case-based review

Eosinophilic granulomatosis with polyangiitis: sequential use of mepolizumab following rituximab for inadequate asthma control despite vasculitis remission

Unexpected and persistent depletion of B lymphocytes CD20 following a minimum dose of anti-CD20 antibody (Rituximab)

Real-life effectiveness of rituximab in different subsets of idiopathic inflammatory myopathies

A short history of anti-rheumatic therapy - VII. Biological agents

Polymyositis following varicella and mumps infection in adults: report of two cases

GISEA: an Italian biological agents registry in rheumatology

Study on the possible role of the -174G>C IL-6 promoter polymorphism in predicting response to rituximab in rheumatoid arthritis

Rheumatoid factor positivity rather than anti-CCP positivity, a lower disability and a lower number of anti-TNFα agents failed are associated with response to rituximab in rheumatoid arthritis

Safety of rituximab in rheumatoid arthritis

Anti-N-methyl-d-aspartate receptor encephalitis: mimicker of lupus and multiple sclerosis

B-cell depletion and primary Sjögren’s syndrome: is there a role for rituximab?

authors

reviewers

Categories

indexing

Keywords